{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=21", "query": { "intervention": "Chemotherapeutic Agent", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 599, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:48:15.942Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04214886", "title": "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Acute Lymphoblastic Leukemia, Adult", "B-cell Lymphoma Refractory", "B-cell Lymphoma Recurrent" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CD19-CD34 CAR transduced T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2019-12-31", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214886" }, { "nct_id": "NCT06896188", "title": "9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anwaar Saeed", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-09-22", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06896188" }, { "nct_id": "NCT07397338", "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Solid Tumors", "Non-small Cell Lung Cancer (NSCLC)", "NSCLC", "Colorectal Cancer (CRC)", "CRC" ], "interventions": [ { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Elironrasib", "type": "DRUG" }, { "name": "Zoldonrasib", "type": "DRUG" }, { "name": "Ivonescimab", "type": "DRUG" }, { "name": "Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)", "type": "DRUG" }, { "name": "cetuximab (Cohort C2 Only)", "type": "DRUG" }, { "name": "Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)", "type": "DRUG" }, { "name": "Daraxonrasib (Cohort B1 only)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 370, "start_date": "2026-01-30", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 8, "location_summary": "Los Angeles, California • Norwich, Connecticut • Saint Paul, Minnesota + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07397338" }, { "nct_id": "NCT05312255", "title": "Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Plasma Cell Myeloma", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma", "Smoldering Plasma Cell Myeloma" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Beta-Adrenergic Antagonist", "type": "DRUG" }, { "name": "Propranolol", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Resistance Training", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2022-06-28", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2025-12-01", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05312255" }, { "nct_id": "NCT07321652", "title": "Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 466, "start_date": "2026-04-30", "completion_date": "2038-09-30", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 224, "location_summary": "Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 180 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Fontana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07321652" }, { "nct_id": "NCT03538899", "title": "Autologous Gene Therapy for Artemis-Deficient SCID", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Severe Combined Immunodeficiency" ], "interventions": [ { "name": "AProArt-CD34", "type": "DRUG" }, { "name": "CliniMACS® CD34 Reagent System cell sorter device", "type": "DEVICE" }, { "name": "Busulfan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": null, "sex": "ALL", "summary": "2 Months and older" }, "enrollment_count": 24, "start_date": "2018-05-31", "completion_date": "2038-06", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538899" }, { "nct_id": "NCT04113616", "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)" ], "interventions": [ { "name": "KRT-232", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2019-09-25", "completion_date": "2023-09-27", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 8, "location_summary": "Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04113616" }, { "nct_id": "NCT05094804", "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Tumor, Solid", "Malignant Neoplasm", "Metastatic Cancer", "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Melanoma", "Head and Neck Squamous Cell Carcinoma", "Leiomyosarcoma", "Liposarcoma" ], "interventions": [ { "name": "OR2805", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoResponse, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2021-09-09", "completion_date": "2024-08-15", "has_results": false, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Austin, Texas • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05094804" }, { "nct_id": "NCT06266299", "title": "A Study of KK2269 in Adult Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "KK2269", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2024-01-18", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Duarte, California • Newport Beach, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06266299" }, { "nct_id": "NCT06625593", "title": "A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BG-C137", "type": "DRUG" }, { "name": "Anticancer Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2024-12-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-15T12:48:15.942Z", "location_count": 6, "location_summary": "Los Angeles, California • New Haven, Connecticut • Rochester, Minnesota + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625593" } ] }